Sato Y, et al. - The dose-limiting toxicity and feasibility of a triweekly capecitabine, oxaliplatin, irinotecan, plus cetuximab (XELOXIRI plus cetuximab) regimen were explored in patients with wild-type KRAS metastatic colorectal cancer (mCRC). The XELOXIRI and cetuximab combination seemed feasible and had an acceptable toxicity profile; neutropenia was the dose-limiting toxicities (DLTs). The 150 mg/m² dose of irinotecan was recommended in this study. The observed promising response rate warranted further investigation.